Interleukin-15 and Soluble Interleukin-15 Receptor α in Coronary Artery Disease Patients: Association with Epicardial Fat and Indices of Adipose Tissue Distribution
Interleukin-15 (IL-15) is a pro-inflammatory cytokine which signals via a specific alpha receptor subunit (IL-15Rα). Increased IL-15 level has been observed in cardiovascular patients and IL-15 immunoreactivity has been detected at vulnerable atherosclerotic plaques. Due to the association between adipose tissue distribution, inflammation and coronary artery disease (CAD), we quantified IL-15 and IL-15Rα in CAD patients with different adiposity and adipose tissue distribution and we evaluated whether epicardial adipose tissue (EAT), a visceral fat depot surrounding and infiltrating myocardium, may be a source of both molecules. IL-15 and IL-15Rα proteins were quantified by enzyme-linked immunosorbent assays. Gene expression of IL-15 and IL-15Rα in EAT depots was evaluated by one colour microarray platform. EAT thickness was measured by echocardiography. Plasmatic IL-15 and IL-15Rα levels were higher in CAD than non-CAD patients. After classification according to adipose tissue distribution, IL-15 was higher in CAD patients with increased abdominal adiposity. Increased level of IL-15Rα was observed both in CAD and non-CAD patients with increased abdominal fat. EAT was a source of IL-15 and IL-15Rα and their expression was higher in CAD patients with increased EAT thickness. In conclusion, our data suggest that circulating levels of IL-15 and IL-15Rα seem to reflect visceral distribution of adipose tissue and that EAT may be a potential source of both IL-15 and IL-15Rα. Future studies on the relationship between IL-15, visceral fat and characteristics of atherosclerotic plaques could help to better understand the complex biology of this cytokine.
References
[1]
Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97: 14–32. doi: 10.1182/blood.v97.1.14
[2]
Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, et al. (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822–2830. doi: 10.1016/1043-4666(94)90167-8
[3]
Dubois S, Magrangeas F, Lehours P, Raher S, Bernard J, et al. (1999) Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression. J Biol Chem 274: 26978–26984. doi: 10.1074/jbc.274.38.26978
[4]
Dubois S, Mariner J, Waldmann TA, Tagaya Y (2002) IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17: 537–547. doi: 10.1016/s1074-7613(02)00429-6
[5]
Mortier E, Bernard J, Plet A, Jacques Y (2004) Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 173: 1681–1688. doi: 10.4049/jimmunol.173.3.1681
[6]
Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, et al. (2008) Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 283: 4189–4199. doi: 10.1074/jbc.m705725200
[7]
Machado Diaz AC, Chico Capote A, Arrieta Aguero CA, Rodriguez Alvarez Y, Garcia Del Barco Herrera D, et al. (2012) Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis 2012: 943156. doi: 10.1155/2012/943156
[8]
Houtkamp MA, van Der Wal AC, de Boer OJ, van Der Loos CM, de Boer PA, et al. (2001) Interleukin-15 expression in atherosclerotic plaques: an alternative pathway for T-cell activation in atherosclerosis? Arterioscler Thromb Vasc Biol 21: 1208–1213. doi: 10.1161/hq0701.092162
[9]
Kaibe M, Ohishi M, Ito N, Yuan M, Takagi T, et al. (2005) Serum interleukin-15 concentration in patients with essential hypertension. Am J Hypertens 18: 1019–1025.
[10]
Gokkusu C, Aydin M, Ozkok E, Tulubas F, Elitok A, et al. (2010) Influences of genetic variants in interleukin-15 gene and serum interleukin-15 levels on coronary heart disease. Cytokine 49: 58–63. doi: 10.1016/j.cyto.2009.09.004
[11]
Pistilli EE, Devaney JM, Gordish-Dressman H, Bradbury MK, Seip RL, et al. (2008) Interleukin-15 and interleukin-15R alpha SNPs and associations with muscle, bone, and predictors of the metabolic syndrome. Cytokine 43: 45–53. doi: 10.1016/j.cyto.2008.04.008
[12]
Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875–880. doi: 10.1038/nature05487
[13]
Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, et al. (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116: 39–48. doi: 10.1161/circulationaha.106.675355
[14]
Despres JP (2012) Body fat distribution and risk of cardiovascular disease: an update. Circulation 126: 1301–1313. doi: 10.1161/circulationaha.111.067264
[15]
Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, et al. (2003) Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108: 2460–2466. doi: 10.1161/01.cir.0000099542.57313.c5
[16]
Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, et al. (2007) Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 121: 132–134. doi: 10.1016/j.ijcard.2006.08.061
[17]
Djaberi R, Schuijf JD, van Werkhoven JM, Nucifora G, Jukema JW, et al. (2008) Relation of epicardial adipose tissue to coronary atherosclerosis. Am J Cardiol 102: 1602–1607. doi: 10.1016/j.amjcard.2008.08.010
[18]
Malavazos AE, Corsi MM, Ermetici F, Coman C, Sardanelli F, et al. (2007) Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis 17: 294–302. doi: 10.1016/j.numecd.2006.01.001
[19]
Dozio E, Dogliotti G, Malavazos AE, Bandera F, Cassetti G, et al. (2012) IL-18 level in patients undergoing coronary artery bypass grafting surgery or valve replacement: which link with epicardial fat depot? Int J Immunopathol Pharmacol 25: 1011–1020.
[20]
Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, et al. (2003) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 11: 304–310. doi: 10.1038/oby.2003.45
[21]
Schejbal V (1989) Epicardial fatty tissue of the right ventricle–morphology, morphometry and functional significance. Pneumologie 43: 490–499.
[22]
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645. doi: 10.1161/circulationaha.109.192644
[23]
Qiao Q, Nyamdorj R (2010) The optimal cutoff values and their performance of waist circumference and waist-to-hip ratio for diagnosing type II diabetes. Eur J Clin Nutr 64: 23–29. doi: 10.1038/ejcn.2009.92
[24]
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808. doi: 10.1172/jci19246
[25]
Ikeoka D, Mader JK, Pieber TR (2010) Adipose tissue, inflammation and cardiovascular disease. Rev Assoc Med Bras 56: 116–121. doi: 10.1590/s0104-42302010000100026
[26]
Quinn LS, Strait-Bodey L, Anderson BG, Argiles JM, Havel PJ (2005) Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int 29: 449–457. doi: 10.1016/j.cellbi.2005.02.005
[27]
Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM (2011) Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 146: 452–454. doi: 10.1016/j.ijcard.2010.10.117
[28]
Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, et al. (2011) Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 9: 433–439. doi: 10.1089/met.2011.0024
[29]
Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, et al. (2012) Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood 120: e1–8. doi: 10.1182/blood-2011-10-384362
[30]
Neely GG, Epelman S, Ma LL, Colarusso P, Howlett CJ, et al. (2004) Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol 172: 4225–4234. doi: 10.4049/jimmunol.172.7.4225
[31]
Budagian V, Bulanova E, Paus R, Bulfone-Paus S (2006) IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17: 259–280. doi: 10.1016/j.cytogfr.2006.05.001
[32]
Mariner JM, Lantz V, Waldmann TA, Azimi N (2001) Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol 166: 2602–2609. doi: 10.4049/jimmunol.166.4.2602
